Iressa black box sought
Public Citizen requests that FDA add a black box warning to Iressa labeling "to state that the drug should be reserved for the same group of patients who were studied in the Phase II trial on which approval was based." FDA approved AstraZeneca's Iressa (gefitinib) for the treatment of advanced non-small cell lung cancer May 5 (1"The Pink Sheet" May 12, p. 3). A black box warning should communicate to "patient[s] that they may be at risk of a fatal lung disease unrelated to NSCLC," Public Citizen says in May 15 letter to Commissioner McClellan. FDA was understood to be considering a black box warning until very late in the review cycle for the drug...
You may also be interested in...
AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005
China ambitiously wants to champion domestic medtech manufacturers in the global market. It also needs to ensure foreign manufacturers do not sustainably dominate its home market – while also benefiting from their technical expertise, for the time being at least. Against that backdrop, new Chinese data laws are being eyed by global medtechs with a certain trepidation.
Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.